Location of brain lesions predicts conversion of clinically isolated syndromes to multiple sclerosis

Objectives: To assess in a large population of patients with clinically isolated syndrome (CIS) the relevance of brain lesion location and frequency in predicting 1-year conversion to multiple sclerosis (MS). Methods: In this multicenter, retrospective study, clinical and MRI data at onset and clinical follow-up at 1 year were collected for 1,165 patients with CIS. On T2-weighted MRI, we generated lesion probability maps of white matter (WM) lesion location and frequency. Voxelwise analyses were performed with a nonparametric permutation-based approach (p < 0.05, cluster-corrected). Results: In CIS patients with hemispheric, multifocal, and brainstem/cerebellar onset, lesion probability map clusters were seen in clinically eloquent brain regions. Significant lesion clusters were not found in CIS patients with optic nerve and spinal cord onset. At 1 year, clinically definite MS developed in 26% of patients. The converting group, despite a greater baseline lesion load compared with the nonconverting group (7 ± 8.1 cm3 vs 4.6 ± 6.7 cm3, p < 0.001), showed less widespread lesion distribution (18% vs 25% of brain voxels occupied by lesions). High lesion frequency was found in the converting group in projection, association, and commissural WM tracts, with larger clusters being in the corpus callosum, corona radiata, and cingulum. Conclusions: Higher frequency of lesion occurrence in clinically eloquent WM tracts can characterize CIS subjects with different types of onset. The involvement of specific WM tracts, in particular those traversed by fibers involved in motor function and near the corpus callosum, seems to be associated with a higher risk of clinical conversion to MS in the short term.

[1]  M. Battaglini,et al.  Voxel-based assessment of differences in damage and distribution of white matter lesions between patients with primary progressive and relapsing-remitting multiple sclerosis. , 2008, Archives of neurology.

[2]  Marco Rovaris,et al.  Effect of early interferon treatment on conversion to definite multiple sclerosis: a randomised study , 2001, The Lancet.

[3]  F Fazekas,et al.  Effect of glatiramer acetate on conversion to clinically definite multiple sclerosis in patients with clinically isolated syndrome (PreCISe study): a randomised, double-blind, placebo-controlled trial , 2009, The Lancet.

[4]  F. Barkhof,et al.  Guidelines for the use of magnetic resonance techniques in monitoring the treatment of multiple sclerosis , 1996, Annals of neurology.

[5]  P M Matthews,et al.  Spatial mapping of T2 and gadolinium-enhancing T1 lesion volumes in multiple sclerosis: evidence for distinct mechanisms of lesion genesis? , 1999, Brain : a journal of neurology.

[6]  AJ Thompson,et al.  Brain lesion location and clinical status 20 years after a diagnosis of clinically isolated syndrome suggestive of multiple sclerosis , 2012, Multiple sclerosis.

[7]  Thomas E. Nichols,et al.  Nonparametric permutation tests for functional neuroimaging: A primer with examples , 2002, Human brain mapping.

[8]  M. Jenkinson Non-linear registration aka Spatial normalisation , 2007 .

[9]  M. Battaglini,et al.  T2 lesion location really matters: a 10 year follow-up study in primary progressive multiple sclerosis , 2010, Journal of Neurology, Neurosurgery & Psychiatry.

[10]  Mark W. Woolrich,et al.  Advances in functional and structural MR image analysis and implementation as FSL , 2004, NeuroImage.

[11]  A Giorgio,et al.  Imaging distribution and frequency of cortical lesions in patients with multiple sclerosis , 2010, Neurology.

[12]  J. Stockman,et al.  Effect of early versus delayed interferon beta-1b treatment on disability after a first clinical event suggestive of multiple sclerosis: a 3-year follow-up analysis of the BENEFIT study , 2009 .

[13]  David H. Miller,et al.  Clinically isolated syndromes , 2012, The Lancet Neurology.

[14]  P. Matthews,et al.  Imaging of axonal damage in multiple sclerosis: Spatial distribution of magnetic resonance imaging lesions , 1997, Annals of neurology.

[15]  M. Battaglini,et al.  T2 lesion location really matters: a 10 year follow-up study in primary progressive multiple sclerosis , 2010, Journal of Neurology, Neurosurgery & Psychiatry.

[16]  H P Hartung,et al.  Treatment with interferon beta-1b delays conversion to clinically definite and McDonald MS in patients with clinically isolated syndromes , 2006, Neurology.

[17]  Joaquín Goñi,et al.  Brain pathways of verbal working memory A lesion–function correlation study , 2009, NeuroImage.

[18]  F. Barkhof,et al.  MRI criteria for MS in patients with clinically isolated syndromes , 2010, Neurology.

[19]  Pablo Villoslada,et al.  Mapping the brain pathways of declarative verbal memory: Evidence from white matter lesions in the living human brain , 2008, NeuroImage.

[20]  S Ropele,et al.  Lesion probability mapping to explain clinical deficits and cognitive performance in multiple sclerosis , 2011, Multiple sclerosis.

[21]  Stephen M. Smith,et al.  Threshold-free cluster enhancement: Addressing problems of smoothing, threshold dependence and localisation in cluster inference , 2009, NeuroImage.

[22]  Moses Rodriguez,et al.  Distinct Patterns of Multiple Sclerosis Pathology Indicates Heterogeneity in Pathogenesis , 1996, Brain pathology.

[23]  F. Barkhof,et al.  Genetic Correlations of Brain Lesion Distribution in Multiple Sclerosis: An Exploratory Study , 2011, American Journal of Neuroradiology.

[24]  M. Jenkinson,et al.  Non-linear optimisation FMRIB Technial Report TR 07 JA 1 , 2007 .

[25]  A. Thompson,et al.  Disability and T2 MRI lesions: a 20-year follow-up of patients with relapse onset of multiple sclerosis. , 2008, Brain : a journal of neurology.

[26]  J. De Keyser,et al.  Treatment with interferon beta-1b delays conversion to clinically definite and McDonald MS in patients with clinically isolated syndromes , 2006, Neurology.

[27]  J H Simon,et al.  Intramuscular interferon beta-1a therapy initiated during a first demyelinating event in multiple sclerosis. CHAMPS Study Group. , 2000, The New England journal of medicine.

[28]  Melvin Greer,et al.  Multiple sclerosis risk after optic neuritis: final optic neuritis treatment trial follow-up. , 2008, Archives of neurology.

[29]  J. Ranjeva,et al.  Cognitive impairment at the onset of multiple sclerosis: relationship to lesion location , 2011, Multiple sclerosis.

[30]  Ludwig Kappos,et al.  Effect of early versus delayed interferon beta-1b treatment on disability after a first clinical event suggestive of multiple sclerosis: a 3-year follow-up analysis of the BENEFIT study , 2007, The Lancet.

[31]  C. Polman,et al.  Infratentorial lesions predict long-term disability in patients with initial findings suggestive of multiple sclerosis. , 2004, Archives of neurology.

[32]  G. Comi,et al.  Comparison of MRI criteria at first presentation to predict conversion to clinically definite multiple sclerosis. , 1997, Brain : a journal of neurology.

[33]  Jeffrey A. Cohen,et al.  Diagnostic criteria for multiple sclerosis: 2010 Revisions to the McDonald criteria , 2011, Annals of neurology.

[34]  À. Rovira,et al.  Baseline MRI predicts future attacks and disability in clinically isolated syndromes , 2006, Neurology.

[35]  Jonathan Taylor,et al.  Statistical mapping analysis of lesion location and neurological disability in multiple sclerosis: application to 452 patient data sets , 2003, NeuroImage.

[36]  F. Barkhof,et al.  Clinical correlations of brain lesion distribution in multiple sclerosis , 2009, Journal of magnetic resonance imaging : JMRI.

[37]  A. Janssens,et al.  Callosal lesion predicts future attacks after clinically isolated syndrome , 2009, Neurology.

[38]  M. Deloire,et al.  Predictive factors for multiple sclerosis in patients with clinically isolated spinal cord syndrome , 2011, Multiple sclerosis.

[39]  Giuseppe Scotti,et al.  The topographical distribution of tissue injury in benign MS: A 3T multiparametric MRI study , 2008, NeuroImage.

[40]  David H. Miller,et al.  Long-term effect of early treatment with interferon beta-1b after a first clinical event suggestive of multiple sclerosis: 5-year active treatment extension of the phase 3 BENEFIT trial , 2009, The Lancet Neurology.

[41]  B. Brownell,et al.  The distribution of plaques in the cerebrum in multiple sclerosis , 1962, Journal of neurology, neurosurgery, and psychiatry.